| 2025 | 1-year risks of cancers associated with COVID-19 vaccination: a large population-based cohort study in South Korea | 천은미; 최명근 | Article |
| 2024 | Autoimmune adverse event following COVID-19 vaccination in Seoul, South Korea | 천은미; 최명근 | Article |
| 2022 | Automated extraction of information of lung cancer staging from unstructured reports of PET-CT interpretation: natural language processing with deep-learning | 최명근 | Article |
| 2022 | Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis | 최명근 | Article |
| 2025 | Broad-Spectrum Adverse Events of Special Interests Based on Immune Response Following COVID-19 Vaccination: A Large-Scale Population-Based Cohort Study | 천은미; 최명근; 서지현 | Article |
| 2025 | Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study | 최명근 | Article |
| 2024 | Extraction of clinical data on major pulmonary diseases from unstructured radiologic reports using a large language model | 최명근 | Article |
| 2022 | Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment | 최명근 | Article |
| 2024 | Prognostic Factors for Predicting Post-COVID-19 Condition in Patients With COVID-19 in an Outpatient Setting | 천은미; 박소정; 신윤영; 최명근 | Article |
| 2024 | Psychiatric adverse events following COVID-19 vaccination: a population-based cohort study in Seoul, South Korea | 천은미; 최명근 | Article |
| 2024 | Safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: non-clinical mouse model and phase I/IIa clinical study | 최명근 | Article |
| 2024 | The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study | 최명근 | Article |
| 2022 | The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea | 최명근 | Article |
